Alnis is using molecular building blocks to shape themselves around a target molecule into a molecular mold, both protecting delicate therapeutics and helping to target them to the right tissues.

Drug delivery start-ups abound, despite the harsh environment for new biopharmaceutical companies. Drug delivery deals are increasing, as are relatively highly valued acquisitions, as larger drug delivery or service companies seek to broaden their tool kits. But for companies who haven't yet proven themselves, dealmaking is difficult in a variety of ways. Credibility is tough to achieve.